Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Yuma Yamada"'
Autor:
Shingo Takada, Toshihisa Anzai, Shintaro Kinugawa, Yuma Yamada, Takaaki Furihata, Arata Fukushima, Hideyoshi Harashima, Takashi Yokota, Takashi Katayama, Mitsue Hibino
Publikováno v:
Mitochondrion. 49:66-72
Mitochondrial function is reduced in skeletal muscles of many patients with systemic diseases and it is difficult to deliver medicinal substances to mitochondria in such tissue. In this study, we report on attempts to develop liposome-based carriers
Publikováno v:
Nucleosides, Nucleotides & Nucleic Acids. 39:141-155
Cardiomyopathy caused by mitochondrial dysfunction associated with the mutation/deletion of mitochondrial DNA has been reported, and nucleic acid therapy targeting cardiac mitochondria represents a possible therapy for treating these diseases. Such a
Publikováno v:
Journal of Pharmaceutical Sciences. 107:647-653
Patients with type I diabetes, which is caused by the destruction of pancreatic islets, now require regular therapeutic injections of insulin. The use of transgene therapy represents an alternate and potent strategy for the treatment of type I diabet
Autor:
Yuma Yamada, Yusuke Sato, Yu Sakurai, Reina Munechika, Hideyoshi Harashima, Fumika Kubota, Satrialdi
Publikováno v:
Journal of pharmaceutical sciences. 109(8)
Mitochondrial delivery of an anticancer drug targeting cancer cells would eventually result in cell death. To achieve this, a drug delivery system targeting mitochondria is needed. We recently developed a MITO-Porter, a liposome that delivers its car
Publikováno v:
Molecular pharmaceutics. 12(12)
For successful mitochondrial transgene expression, two independent processes, i.e., developing a mitochondrial gene delivery system and construction of DNA vector to achieve mitochondrial gene expression, are required. To date, very few studies deali
Autor:
Kohei Nakamura, Mamoru Hyodo, Hideyoshi Harashima, Yuma Yamada, Jiro Abe, Sanae Haga, Michitaka Ozaki
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 213
We herein report on a mitochondrial therapeutic effect based on the delivery of coenzyme Q(10) (CoQ(10)), an anti-oxidant, to in vivo mitochondria using a MITO-Porter, a liposome-based mitochondrial delivery system that functions via membrane fusion.
Publikováno v:
Journal of Pharmacy and Pharmacology. 58:431-437
A multifunctional envelope-type nano device (MEND) was developed for use as an efficient non-viral system for the delivery of plasmid DNA (pDNA) using octaarginine (R8) as an internalizing ligand. Three types of R8-MENDs were prepared, co-encapsulati
Publikováno v:
Biomaterials. 52
The cellular uptake pathway for a gene vector is an important factor in transgene expression. We previously constructed an original gene vector, multifunctional envelope-type nano device (MEND). The use of octaarginine (R8), a cell-penetrating peptid
Publikováno v:
International Journal of Pharmaceutics. 299:34-40
The production of an exogenous protein by the transfection of a plasmid DNA encoding the protein was kinetically analyzed, to determine the efficiency of the transfection. Cultured NIH3T3 or HeLa cells, and the luciferase protein were used as a model
Autor:
Natsumi Noda, Takeaki Ozawa, Kazuo Umezawa, Sanae Haga, Naoki Morita, Michitaka Ozaki, Hiroshi Inoue, Yuma Yamada, Riichiro Abe, Yuka Inaba, Izuru Nagashima
Publikováno v:
Antioxidantsredox signaling. 21(18)
Aims: Liver injury and regeneration involve complicated processes and are affected by various physio-pathological factors. We investigated the mechanisms of steatosis-associated liver injury and delayed regeneration in a mouse model of partial hepate